Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Hemab Therapeutics HoldingsCOAG | Open-market buy | 06/15–06/16 | 06/17 | 67,669 sh2 trades | $24.97avg. | $1,689,818.48 | +1.1% | |
10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 06/15–06/16 | 06/17 | 67,669 sh2 trades | $24.97avg. | $1,689,818.48 | +1.1% |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 06/15–06/16 | 06/17 | 67,669 sh2 trades | $24.97avg. | $1,689,818.48 | +1.1% | |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 06/15–06/16 | 06/17 | 67,669 sh2 trades | $24.97avg. | $1,689,818.48 | +1.1% | |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/19–05/20 | 05/21 | 4,798 sh2 trades | $24.96avg. | $119,776.18 | +0.1% | |
10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/19–05/20 | 05/21 | 4,798 sh2 trades | $24.96avg. | $119,776.18 | +0.1% |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/19–05/20 | 05/21 | 4,798 sh2 trades | $24.96avg. | $119,776.18 | +0.1% | |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/19–05/20 | 05/21 | 4,798 sh2 trades | $24.96avg. | $119,776.18 | +0.1% | |
RA Capital Healthcare Fund10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/12 | 05/14 | 6,387 sh | $24.90 | $159,036.3 | +0.1% |
Ra Capital Management10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/12 | 05/14 | 6,387 sh | $24.90 | $159,036.3 | +0.1% |
Peter Kolchinsky10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/12 | 05/14 | 6,387 sh | $24.90 | $159,036.3 | +0.1% |
Rajeev M. Shah10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/12 | 05/14 | 6,387 sh | $24.90 | $159,036.3 | +0.1% |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/07–05/11 | 05/11 | 51,258 sh5 trades | $24.75avg. | $1,268,594.26 | +0.8% | |
10% Owner | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/07–05/11 | 05/11 | 51,258 sh5 trades | $24.75avg. | $1,268,594.26 | +0.8% |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/07–05/11 | 05/11 | 51,258 sh5 trades | $24.75avg. | $1,268,594.26 | +0.8% | |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/07–05/11 | 05/11 | 51,258 sh5 trades | $24.75avg. | $1,268,594.26 | +0.8% | |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/04–05/06 | 05/06 | 2,840,429 sh6 trades | $18.39avg. | $52,222,945.65 | +81.8% | |
Director | Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/04–05/06 | 05/06 | 2,840,429 sh6 trades | $18.39avg. | $52,222,945.65 | +81.8% |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/04–05/06 | 05/06 | 2,840,429 sh6 trades | $18.39avg. | $52,222,945.65 | +81.8% | |
Hemab Therapeutics HoldingsCOAG | Open-market buy | 05/04–05/06 | 05/06 | 2,840,429 sh6 trades | $18.39avg. | $52,222,945.65 | +81.8% |
